HFpEF With Pulmonary Vascular Disease: A New Phenotype? HFpEF With Pulmonary Vascular Disease: A New Phenotype?
What do we know about the emerging clinical syndrome of pulmonary hypertension in HFpEF, and what do we still need to learn? This brief summarizes current knowledge of this newly recognized problem.European Heart Journal
Authors: Wilkens H, Held M Abstract Exertional dyspnea is a nonspecific symptom with a variety of underlying causes. It can be challenging to differentiate a beginning cardiac disease from a pulmonary disease or from deconditioning alone. In the presence of obesity, the overall assessment is even more difficult. Rare diseases, such as pulmonary hypertension with dyspnea on exertion as the cardinal symptom are usually diagnosed late in the course of disease. The starting point of a successful evaluation is a thorough patient history. The combination of symptoms, clinical signs and findi...
In this study, the number of circulating endothelial progenitor cells (EPC) is lower in naïve pulmonary artery hypertension (PAH) patients, and treatment of PAH-tar geted drugs increased EPC levels in the blood of PAH patients. However, there is no elevation of circulating EPC in chronic thromboembolic pulmonary hypertension patients.
ConclusionFrom the present investigation it could be concluded that S100A4/Mts1 and its associated proteins are involved in the evolution of MCT-induced PAH in rats and fluoxetine inhibits MCT-induced PAH in rats mainly through S100A4/RAGE signaling axis and involved factors.
Dobutamine stress echocardiography (DSE) using the full protocol (40 μg ± atropine) has been classically used to detect functionally significant coronary artery disease (CAD) in subjects referred for evaluation of chest pain. Earlier studies showed moderate sensitivity and specificity of DSE that could be enhanced using quantified stress echo using tissue Do ppler imaging .
Pulmonary hypertension (PH) is a progressive disease involving the pulmonary arteries resulting increased pulmonary artery pressure, right heart failure and ultimately death. PH is defined by resting pulmonary arterial pressure ≥ 25mmHg and requires right heart catherization to be diagnosed. PH is classified based upon etiology into five groups: Group I- pulmonary arterial hypertension, Group II-PH due to left heart disease, Group III- PH due to chronic lung disease and or hypoxeia, Group IV- PH due to chronic thromboemb olic pulmonary hypertension and Group V- PH due to unclear multifactorial mechanisms [1,2] (reviewer#1, comment#1).
Publication date: Available online 18 July 2018Source: Canadian Journal of CardiologyAuthor(s): Christine L. D’Arsigny, Stephen L. Archer
Conclusions: To the best of our knowledge, this is the largest dataset to describe reference ranges of TRV and their clinical determinants in healthy adults years. The determined cut-off value of 2.55 m/s of this study has to be confirmed in specific pathologies such as patients at risk of PH.Respiration
ConclusionsThis is the first time that structural studies on the full length protein evidenced the assembly of PDE5 in tetramers in addition to the expected dimers.General SignificanceThe assembly of PDE5 in tetramers in platelets, beside the dimers, opens the possibility to alternative assembly/allosteric regulation of this enzyme, as component of large signaling complexes, in all cellular districts in which PDE5 is present.
Publication date: Available online 17 July 2018Source: American Heart JournalAuthor(s): Geoff Strange, David S Celermajer, Tom Marwick, David Prior, Marcus Ilton, Jim Codde, Gregory M Scalia, Simon Stewart, Max Bulsara, Eli Gabbay, David PlayfordAbstractThe National Echocardiography Database Australia (NEDA) is a new echocardiography database collecting digital measurements on both a retrospective and prospective basis. To date, echocardiographic data from 435,133 individuals (aged 61.6 ± 17.9 years) with linkage to 59,725 all-cause deaths during a median of 40 months follow-up have been collecte...